JP2004517847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517847A5 JP2004517847A5 JP2002551530A JP2002551530A JP2004517847A5 JP 2004517847 A5 JP2004517847 A5 JP 2004517847A5 JP 2002551530 A JP2002551530 A JP 2002551530A JP 2002551530 A JP2002551530 A JP 2002551530A JP 2004517847 A5 JP2004517847 A5 JP 2004517847A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- phenyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- -1 2 -cyclopropyl Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- YRPJPJYKNGUMJQ-UHFFFAOYSA-N 2-[4-(4,9-diethoxy-3-oxo-1h-benzo[f]isoindol-2-yl)phenyl]-n-(4-fluorophenyl)sulfonylacetamide Chemical compound O=C1C2=C(OCC)C3=CC=CC=C3C(OCC)=C2CN1C(C=C1)=CC=C1CC(=O)NS(=O)(=O)C1=CC=C(F)C=C1 YRPJPJYKNGUMJQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 101150109738 Ptger4 gene Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- XREWXJVMYAXCJV-UHFFFAOYSA-N n-(benzenesulfonyl)-2-[4-(4,9-diethoxy-3-oxo-1h-benzo[f]isoindol-2-yl)phenyl]acetamide Chemical compound O=C1C2=C(OCC)C3=CC=CC=C3C(OCC)=C2CN1C(C=C1)=CC=C1CC(=O)NS(=O)(=O)C1=CC=CC=C1 XREWXJVMYAXCJV-UHFFFAOYSA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0031295.9A GB0031295D0 (en) | 2000-12-21 | 2000-12-21 | Naphthalene derivatives |
| PCT/GB2001/005706 WO2002050033A1 (en) | 2000-12-21 | 2001-12-20 | Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004517847A JP2004517847A (ja) | 2004-06-17 |
| JP2004517847A5 true JP2004517847A5 (enExample) | 2005-12-22 |
| JP4398150B2 JP4398150B2 (ja) | 2010-01-13 |
Family
ID=9905625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002551530A Expired - Fee Related JP4398150B2 (ja) | 2000-12-21 | 2001-12-20 | ベンゾ（ｆ）イソインドール誘導体およびそのＥＰ４受容体リガンドとしての使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7173047B2 (enExample) |
| EP (1) | EP1343759A1 (enExample) |
| JP (1) | JP4398150B2 (enExample) |
| AU (1) | AU2002217287A1 (enExample) |
| GB (1) | GB0031295D0 (enExample) |
| WO (1) | WO2002050033A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0103269D0 (en) * | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| BR0309200A (pt) | 2002-04-12 | 2005-02-22 | Pfizer | Uso de ligandos receptores ep4 no tratamento de doenças envolvidas com a il-6 |
| WO2004073589A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4) |
| JP2007533723A (ja) * | 2004-04-20 | 2007-11-22 | ファイザー・プロダクツ・インク | α２δリガンドを含む組合せ |
| ATE533766T1 (de) | 2005-05-19 | 2011-12-15 | Merck Canada Inc | Chinolinderivate als ep4-antagonisten |
| UY30121A1 (es) | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
| SG169378A1 (en) * | 2006-02-03 | 2011-03-30 | Glaxo Group Ltd | Benzoisoindole derivatives for the treatment of pain |
| GB0602900D0 (en) * | 2006-02-13 | 2006-03-22 | Glaxo Group Ltd | Novel Compounds |
| GB0615111D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel compounds |
| GB0615105D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel compounds |
| GB0616498D0 (en) * | 2006-08-18 | 2006-09-27 | Glaxo Group Ltd | Novel compounds |
| JP5069752B2 (ja) | 2006-12-15 | 2012-11-07 | グラクソ グループ リミテッド | Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体 |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| WO2010087425A1 (ja) | 2009-01-30 | 2010-08-05 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
| US20120190637A1 (en) | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| WO2014143591A1 (en) * | 2013-03-12 | 2014-09-18 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors |
| CA2920856C (en) | 2013-08-09 | 2026-03-03 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
| JP7816164B2 (ja) | 2020-11-13 | 2026-02-18 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997005091A1 (en) * | 1995-07-26 | 1997-02-13 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives and drugs comprising the same as active ingredients |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| AU6836200A (en) * | 1999-08-10 | 2001-03-05 | Glaxo Group Limited | Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer |
| GB0031302D0 (en) * | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
-
2000
- 2000-12-21 GB GBGB0031295.9A patent/GB0031295D0/en not_active Ceased
-
2001
- 2001-12-20 US US10/450,639 patent/US7173047B2/en not_active Expired - Fee Related
- 2001-12-20 WO PCT/GB2001/005706 patent/WO2002050033A1/en not_active Ceased
- 2001-12-20 EP EP01271356A patent/EP1343759A1/en not_active Withdrawn
- 2001-12-20 AU AU2002217287A patent/AU2002217287A1/en not_active Abandoned
- 2001-12-20 JP JP2002551530A patent/JP4398150B2/ja not_active Expired - Fee Related
-
2006
- 2006-07-14 US US11/486,698 patent/US20060252799A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517099A5 (enExample) | ||
| RU2306309C2 (ru) | Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний | |
| TWI316942B (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
| TW200523250A (en) | Compounds for inflammation and immune-related uses | |
| JP2004517098A5 (enExample) | ||
| US20080033033A1 (en) | 8-azaprostaglandin derivatives and medical use thereof | |
| JP2002543185A5 (enExample) | ||
| RU2003102612A (ru) | N-окиси в качестве пролекарств производных 4-фенилпиридина, являющихся натагонистами рецептора nk-1 | |
| JP2009536660A5 (enExample) | ||
| HU230421B1 (hu) | Csonttömegveszteséggel kapcsolatos betegségek kezelésére adható, EP4 agonistát tartalmazó gyógyászati készítmények és hatóanyagként alkalmazható vegyületek | |
| JP2015227331A (ja) | ５−置換イソインドリン化合物 | |
| JP2011509309A5 (enExample) | ||
| RU2002132253A (ru) | Производные 2-ацилиндола, их применение (варианты) и способ получения, лекарственное средство и способ его получения, противоопухолевое средство и способ его получения | |
| JP2006507355A5 (enExample) | ||
| CN107530352A (zh) | 使用茚满乙酸衍生物治疗肝病的方法 | |
| RU2007108863A (ru) | Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3 | |
| WO2001085167A1 (en) | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | |
| JP5315336B2 (ja) | 精神疾患治療用の新規化合物とその調剤及び使用 | |
| JPWO2006043655A1 (ja) | 吸入用医薬組成物 | |
| JPWO2006025324A1 (ja) | トロパン化合物およびそれらを有効成分として含有する医薬組成物 | |
| JP2006503056A5 (enExample) | ||
| EP0412901B1 (fr) | Utilisation de trifluorométhyl-phényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles de la motricité intestinale | |
| WO1997009301A1 (en) | 2-acylaminobenzamide derivatives and preventive and remedy for diseases caused by the supermultiplication of vascular intimal cells | |
| WO2004089411A1 (ja) | 脊柱管狭窄症治療剤 | |
| JP2006089443A (ja) | インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤 |